Ulrike Bauer1, Carolin Mogler2, Rickmer F Braren3, Hana Algül1, Roland M Schmid1, Ursula Ehmer2. 1. Department of Internal Medicine II, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. 2. Institute of Pathology, Technische Universität München, Munich, Germany. 3. Institute for Diagnostic and Interventional Radiology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
Abstract
BACKGROUND: Fibrolamellar carcinoma (FLC) is a rare malignancy of the liver that differs from typical hepatocellular carcinoma (HCC) in several aspects such as the absence of underlying liver disease and occurrence in younger patients. Even though the survival rates in FLC are slightly better than in typical HCC, the prognosis of metastatic FLC remains deleterious. Several reports suggest that systemic chemotherapy regimens can successfully be used to halt disease progression in FLC, while targeted tumor therapy with sorafenib seems to be of limited efficiency. However, results from controlled clinical trials investigating systemic therapies in FLC are virtually nonexistent. Therefore, the choice of treatment often relies on case series with limited numbers of patients. Immunotherapy with checkpoint inhibitors is an emerging cancer therapy in several solid malignancies including HCC. Currently, there do not exist any reports on the use of checkpoint inhibitors in FLC. CASE REPORT: Here, we describe a case of advanced FLC in a young man receiving immunotherapy, who progressed after 3 months of treatment - similar to 2 other patients with advanced FLC at our hospital. CONCLUSION: While immunotherapy seems to be a promising treatment with limited side effects in several other tumor entities, there is currently no data supporting tumor response in FLC.
BACKGROUND: Fibrolamellar carcinoma (FLC) is a rare malignancy of the liver that differs from typical hepatocellular carcinoma (HCC) in several aspects such as the absence of underlying liver disease and occurrence in younger patients. Even though the survival rates in FLC are slightly better than in typical HCC, the prognosis of metastatic FLC remains deleterious. Several reports suggest that systemic chemotherapy regimens can successfully be used to halt disease progression in FLC, while targeted tumor therapy with sorafenib seems to be of limited efficiency. However, results from controlled clinical trials investigating systemic therapies in FLC are virtually nonexistent. Therefore, the choice of treatment often relies on case series with limited numbers of patients. Immunotherapy with checkpoint inhibitors is an emerging cancer therapy in several solid malignancies including HCC. Currently, there do not exist any reports on the use of checkpoint inhibitors in FLC. CASE REPORT: Here, we describe a case of advanced FLC in a young man receiving immunotherapy, who progressed after 3 months of treatment - similar to 2 other patients with advanced FLC at our hospital. CONCLUSION: While immunotherapy seems to be a promising treatment with limited side effects in several other tumor entities, there is currently no data supporting tumor response in FLC.
Authors: Ahmed O Kaseb; Mohamed Shama; Ibrahim Halil Sahin; Ajay Nooka; Hesham M Hassabo; Jean-Nicolas Vauthey; Thomas Aloia; James L Abbruzzese; Ishwaria M Subbiah; Filip Janku; Steven Curley; Manal M Hassan Journal: Oncology Date: 2013-09-19 Impact factor: 2.935
Authors: Gabriel G Malouf; Laurence Brugières; Marie-Cécile Le Deley; Sandrine Faivre; Monique Fabre; Valérie Paradis; Isabelle Aerts; Christophe Le Tourneau; Chantal Dreyer; Sophie Branchereau; Jacques Belghiti; Eric Raymond Journal: Cancer Date: 2012-03-13 Impact factor: 6.860
Authors: Tobias Eggert; Katherine A McGlynn; Austin Duffy; Michael Peter Manns; Tim F Greten; Sean F Altekruse Journal: Gut Date: 2013-05-25 Impact factor: 23.059
Authors: Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa Journal: Gastrointest Cancer Res Date: 2013-01
Authors: Yehuda Z Patt; Manal M Hassan; Richard D Lozano; Thomas D Brown; J Nicolas Vauthey; Steven A Curley; Lee M Ellis Journal: J Clin Oncol Date: 2003-02-01 Impact factor: 44.544
Authors: Francesco Stipa; Sam S Yoon; Kui Hin Liau; Yuman Fong; William R Jarnagin; Michael D'Angelica; G Abou-Alfa; Leslie H Blumgart; Ronald P DeMatteo Journal: Cancer Date: 2006-03-15 Impact factor: 6.860
Authors: Timothy A Dinh; Alan F Utria; Kevin C Barry; Rosanna Ma; Ghassan K Abou-Alfa; John D Gordan; Elizabeth M Jaffee; John D Scott; Jessica Zucman-Rossi; Allison F O'Neill; Mark E Furth; Praveen Sethupathy Journal: Nat Rev Gastroenterol Hepatol Date: 2022-02-21 Impact factor: 73.082
Authors: Anastasia Lemekhova; Daniel Hornuss; Georgios Polychronidis; Philipp Mayer; Christian Rupp; Thomas Longerich; Karl-Heinz Weiss; Markus Büchler; Arianeb Mehrabi; Katrin Hoffmann Journal: World J Surg Oncol Date: 2020-05-12 Impact factor: 2.754